The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase 1 trial presented by researchers at The University of Texas MD Anderson Cancer Center.